Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the efficacy and safety of ibrexafungerp versus placebo for acute vulvovaginal candidiasis (VVC) treatment. Design: Global phase 3, randomised, placebo‐controlled superiority study. Setting: Study sites in the USA (n = 19) and Bulgaria (n = 18). Population: Female patients aged ≥12 years with acute VVC and a vulvovaginal signs and symptoms (VSS) score ≥4 at baseline. Methods: Patients were randomly assigned 2:1 to ibrexafungerp (300 mg twice for 1 day) or placebo. Main outcome measures: The primary endpoint was the percentage of patients with a clinical cure (VSS = 0) at the test‐of‐cure visit (day 11 ± 3). Secondary endpoints included percentages of patients with mycological eradication, clinical cure and mycological eradication (overall success), clinical improvement (VSS ≤1) at test‐of‐cure visit, and complete resolution of symptoms at follow‐up visit (day 25 ± 4). Results: At the test‐of‐cure visit, patients receiving ibrexafungerp had significantly higher rates of clinical cure (63.3% [119/188] versus 44.0% [37/84]; P = 0.007), mycological eradication (58.5% [110/188] versus 29.8% [25/84]; P < 0.001), overall success (46.1% [82/188] versus 28.4% [23/84]; P = 0.022) and clinical improvement (72.3% [136/188] versus 54.8% [46/84]; P = 0.01) versus those receiving placebo. Symptom resolution was sustained and further increased with ibrexafungerp (73.9%) versus placebo (52.4%) at follow‐up (P = 0.001). Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mild to moderate in severity. Conclusions: Ibrexafungerp demonstrated statistical superiority over placebo for the primary and secondary endpoints. Ibrexafungerp is a promising novel, well‐tolerated and effective oral 1‐day treatment for acute VVC. Tweetable abstract: Ibrexafungerp is statistically superior to placebo for the treatment of vulvovaginal candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
Self-citationYano, J., Sobel, J. D., Nyirjesy, P., Sobel, R., Williams, V. L., Yu, Q., Noverr, M. C., & Fidel, P. L. (2019) · BMC Women's Health · doi:10.1186/s12905-019-0748-8 · Cited by 270
Self-citationAspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225
Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole
Sobel, J. D., Kapernick, P. S., Zervos, M., Reed, B. D., Hooton, T., Soper, D., Nyirjesy, P., Heine, M. W., Willems, J., Panzer, H., et al. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.115116 · Cited by 158
Self-citationHasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis)
Mendling, W. (2015) · Mycoses · doi:10.1111/myc.12292 · Cited by 117
Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66
Self-citationOral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46
Self-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Cited by
Rybak, J. M., Cuomo, C. A., & David Rogers, P. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102208 · Cited by 113
“auris, clinical experience with ibrexafungerp remains limited and it is currently only indicated as an orally administered treatment for vulvovaginal candidiasis [14].”
BackgroundNew Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Sobel, J. D. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad002 · Cited by 23
Self-citationHow do I manage refractory invasive pulmonary aspergillosis
Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12
Shen, J., Zhang, C., Lin, Y., Zhang, C., Zhou, J., Zhou, Y., Gou, L., Liao, G., Zhu, Z., Cheng, L., et al. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13740-1
“Over the past 30 years, only one novel antifungal agent, ibrexafungerp, has been approved for the treatment of vulvovaginal candidiasis (Sobel et al. 2022).”
Metadata
- Authors
- Sobel, R., Nyirjesy, P., Ghannoum, M., Delchev, D., Azie, N., Angulo, D., Harriott, I., Borroto‐Esoda, K., & Sobel, J.
- Venue
- BJOG: An International Journal of Obstetrics & Gynaecology
- Publisher
- Wiley
- Published
- 2021-11-08
- Volume
- 129
- Issue
- 3
- Pages
- 412-420
- ISSN
- 0306-5456 (ISSN-L)
- 1470-0328
- 1471-0528
- OpenAlex
- W3206023908
- Cited by
- 55
- References
- 9
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.